Chinese Japanese Germany Korea

Dacomitinib (PF299804)

Description Biological activity Clinical Study References
Dacomitinib (PF299804)
Dacomitinib (PF299804) structure
Chemical Name:
Dacomitinib (PF299804)
PF299;PF299804;Dacomitinib;PF-00299804;PF-00299804-03;PF299804, PF299);Dacomitinib, >=98%;DacoMitinib,PF299804;DacoMitinib (PF-00299804);DacoMitinib (PF299804, PF299)
Molecular Formula:
Formula Weight:
MOL File:

Dacomitinib (PF299804) Properties

CAS DataBase Reference


HS Code  29335990

Dacomitinib (PF299804) price More Price(6)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TCI Chemical D5450 Dacomitinib >98.0%(HPLC) 1110813-31-4 50mg $150 2018-11-22 Buy
TCI Chemical D5450 Dacomitinib >98.0%(HPLC) 1110813-31-4 250mg $451 2018-11-22 Buy
Cayman Chemical 9001879 PF-299804 ≥98% 1110813-31-4 5mg $158 2018-11-19 Buy
Cayman Chemical 9001879 PF-299804 ≥98% 1110813-31-4 1mg $35 2018-11-19 Buy
Cayman Chemical 9001879 PF-299804 ≥98% 1110813-31-4 10mg $280 2018-11-19 Buy

Dacomitinib (PF299804) Chemical Properties,Uses,Production


Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib. 

Biological activity

Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2.
Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.

Clinical Study

Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing.
Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status.
Additionally, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).


Ellis, Peter M,, et al. "Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. " Lancet Oncology 15.12(2014):1379.
Kalous, O, et al. "Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. " Molecular Cancer Therapeutics11.9(2012):1978.


PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.


ChEBI: A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin 1-yl)but-2-enoyl group.

Dacomitinib (PF299804) Preparation Products And Raw materials

Raw materials

Preparation Products

Dacomitinib (PF299804) Suppliers

Global( 168)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37127788 CHINA 493 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 CHINA 892 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24192 60
career henan chemical co
+86-371-86658258 CHINA 27142 58
08657186217390 CHINA 308 58
Hubei Jusheng Technology Co.,Ltd.
027-59599243 CHINA 28237 58
Shandong chuangyingchemical Co., Ltd.
13156170209 CHINA 4419 58
Standardpharm Co. Ltd.
0714-3992388 CHINA 13061 58
BOC Sciences
1-631-614-7828 United States 20116 58
ExcelChemical (Shanghai) Chemical Technology Co., Ltd. +86 13671938079; QQ:16313380
+86-021-50829787 China 40 55

View Lastest Price from Dacomitinib (PF299804) manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-12-23 Dacomitinib (PF299804)
US $2.00 / kg 1kg 99% 100kg career henan chemical co

1110813-31-4(Dacomitinib (PF299804))Related Search:

  • PF-299804 (Dacomitinib,PF-00299804)
  • PF299804, PF299)
  • Dacomitinib
  • PF-00299804-03
  • PF-00299804
  • DacoMitinib (PF-00299804)
  • DacoMitinib,PF299804
  • DacoMitinib (PF299804,PF-00299804)
  • DacoMitinib (PF299804, PF299)
  • (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Dacomitinib (PF299804, PF299)
  • (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquizolin-6-yl)-4-(piperidin-1-yl)but-2-eMide
  • dacomitinib (pan-HER inhibitor)
  • (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
  • Dacomitinib, >=98%
  • 2-Butenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-
  • PF299
  • (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
  • PF299804
  • (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
  • Dacomitinib, 98%, a potent irreversible ErbB inbibitor
  • 1110813-31-4
  • C24H25ClFN5O2
  • -
  • Anti-cancer&immunity
  • Inhibitors
Copyright 2017 © ChemicalBook. All rights reserved